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Parental Refusal of Surgery in an
Infant With Tricuspid Atresia
Alexander A. Kon, MD,a Angira Patel, MD, MPH,b Steven Leuthner, MD, MA,c John D. Lantos, MDd

We present a case of a fetal diagnosis of tricuspid atresia (TA). The
pregnant woman and her husband requested that the baby be treated
with only palliative care. The cardiologist did not think it would be
appropriate to withhold life-prolonging surgery once the infant was born.
The neonatologist argued that outcomes for TA are similar to those for
hypoplastic left heart syndrome, and the standard practice at the institution
was to allow parents to choose surgery or end-of-life care for those infants.
The team requested an ethics consultation to assist in determining whether
forgoing life-prolonging interventions in this case would be ethically
supportable. In this article, we ask a pediatric intensivist, a pediatric
cardiologist, and a neonatologist to discuss the ethics of withholding lifesustaining treatment of a baby with TA.

Advances in fetal diagnosis now allow
couples who are having a baby to
anticipate the decisions that will need
to be made after birth. If the prenatal
diagnosis is made early enough in
pregnancy, then 1 option may be
to terminate the pregnancy. When
pregnancies are carried to term, then
choices might be necessary about
whether to pursue life-sustaining
treatment or, instead, to provide only
comfort-oriented palliative care. In
the abstract, the ethical principles that
should guide such decisions are clear.
If the treatment is clearly beneficial,
then the baby’s right to treatment
should outweigh parents’ right to
refuse. If, instead, the outcomes
that are anticipated with treatment
are ambiguous or uncertain, then
the parents’ choices determine the
course of action. In practice, those
principles are difficult to apply.
Doctors may disagree about whether
a particular treatment of a particular
condition is sufficiently successful so
that parental refusal should not be
permitted. Tricuspid atresia (TA) is 1
such condition. In this Ethics Rounds,
we present a case of TA and seek

expert commentary on the ethics from
an intensivist, a cardiologist, and a
neonatologist, all of whom are also
bioethicists.

THE CASE
A young married woman was
pregnant with her first child. During
routine prenatal care, an ultrasound
was performed and there was concern
that the child might have congenital
heart disease. A fetal echocardiogram
was performed at ~24 weeks’
gestation that revealed tricuspid
atresia (TA). The cardiologist met
with the parents to discuss their son’s
condition, explaining the standard
surgical approach and long-term
prognosis. At home, the parents
researched the proposed surgery on
the Internet and learned that many
parents decline this surgery. At their
next appointment, the couple told the
cardiologist that they did not want
their baby to get the surgery and
instead would focus on making him
comfortable.
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ETHICS ROUNDS

The perinatal team, including
the cardiologist, neonatologist,
obstetrician, and others, met to
discuss the case. The cardiologist
voiced concerns about the father’s
decision, stating that she did not
think it would be appropriate to
withhold life-prolonging surgery
once the infant was born. The
neonatologist argued that outcomes
for TA are similar to those for
hypoplastic left heart syndrome
(HLHS), and the standard practice at
the institution was to allow parents
to choose surgery or end-of-life
(EOL) care for those infants. Based
on the principle that equal patients
should be treated equally, he argued
that allowing the parents to decline
surgery would be appropriate.
The team requested an ethics
consultation to assist in determining
whether forgoing life-prolonging
interventions in this case would be
ethically supportable.

Alex Kon, MD, Pediatric Intensivist,
Comments
When making life-and-death choices
for an infant, parents and providers
must consider primarily the infant’s
best interest.1 However, such
decisions are highly value laden.
Different parents, and different
providers, may judge the same
situation very differently. To some,
the benefits of prolonging life,
even for a short time in the face of
significant morbidity, outweigh the
burdens of even significant suffering.
For others, minimizing suffering is a
more important goal than prolonging
life. In such cases, there is often no
single right answer. Furthermore,
although the best interests of the
infant are central in decision-making,
the interests of the parents, siblings,
and other may also be considered.2,3
The American Academy of
Pediatrics recognizes that most such
decisions fall into a gray area in
which several goals of care may be
ethically permissible. The academy
recommends that providers seek

to overrule parents only when
parents make decisions that are
clearly contrary to the infant’s best
interests.1,2 Merely disagreeing with
parents’ values and preferences is
insufficient. This standard requires
that providers intervene only
when parents make choices that
are inconsistent with decisions
reasonable people would make.
Providers lack the authority to
unilaterally overrule parents who
decline life-prolonging interventions
(except in rare, emergent situations).
When providers believe that parents
are clearly acting contrary to the
infant’s best interests, they may seek
a court order to provide therapy
that they believe is necessary and
appropriate. The decision to seek
a court order should not be made
lightly. In general, courts are more
willing to authorize treatment over
parental objection if the treatment is
of short duration, there is consensus
in the medical community regarding
the medically appropriate treatment,
the prognosis with treatment
is favorable and there is a high
likelihood that the child would have
a relatively normal life, and without
treatment there is a high likelihood
that the child would die. With this
understanding, we turn to the case at
hand.
Infants with single-ventricle (SV)
physiology such as TA and HLHS
whose parents choose life-prolonging
interventions follow a similar
surgical course. Both cardiac lesions
warrant surgical intervention
within the first few days of life that
includes placement of a surgical
shunt to supply pulmonary blood
flow (note that experts continue to
develop new surgical and hybrid
approaches for initial management).
The initial surgery is usually followed
by ≥2 additional cardiac surgeries,
generally including a bidirectional
cavopulmonary anastomosis (Glenn
procedure) by 6 months of life
and a Fontan procedure before
5 years of age. Many affected infants

have feeding difficulties and high
caloric requirements for growth,
so a gastrostomy tube is often
needed to maintain adequate intake.
Potential complications of multiple
cardiac surgeries necessitating
cardiopulmonary bypass include
heart failure, arrhythmias (which
may necessitate pacemaker
placement), and stroke with resultant
neurologic deficits. Furthermore,
infants with SVs have a shorter than
average life expectancy because of
early heart and liver failure. Because
infants with TA generally have an
adequately sized left ventricle, in
contrast to infants with HLHS, there
may be reason to believe that infants
with TA would be less likely to need
cardiac transplantation later in life
than infants with HLHS; however,
there are insufficient data to draw
firm conclusions.
As noted by the obstetrician, the
standard for infants with HLHS
generally is to allow parents to
choose either life-prolonging
interventions or EOL care. In the
case of HLHS, the option of EOL
care is generally considered
ethically permissible because
surgical outcomes are suboptimal
(5-year survival is ~80%,4–7
and there is significant risk of
neurodevelopmental and other
disorders among survivors8–15),
experts in the field are divided
between favoring life-prolonging
interventions or EOL care,16–18
and many believe that infants with
HLHS endure significant suffering
throughout their treatment course.
For these reasons, although there
remains debate about appropriate
care for infants with HLHS,19–21
in general parents are given the
choice between life-prolonging
interventions or EOL care.
Surgical outcomes for infants with
TA are similar when compared with
outcomes for HLHS. Although it is
less well studied than HLHS, 5-year
postoperative survival in TA is
~80%,22–25 and survivors are also

Downloaded from www.aappublications.org/news by guest on September 11, 2019
2

KON et al

at risk for neurodevelopmental and
other disorders.26 Therefore, when
the obstetrician argued that infants
with TA should be treated similarly
to those with HLHS, his reasoning
had some merit.
In this case, however, we must look
not only at outcomes for infants who
undergo life-prolonging interventions
but also at outcomes for those whose
parents decline life-prolonging
intervention. In the case of HLHS,
95% of infants will die within the
first month of life.27 Because of
the rapid demise of these infants,
providers can deliver high-quality
palliative care, and the pain and
suffering of infants during the dying
process can be minimized. Therefore,
EOL care is generally considered
a reasonable alternative to lifeprolonging interventions for infants
with HLHS. Data also suggest that
when given complete information,
parents are split regarding the
choices they make.28–32 Furthermore,
when experts are asked what they
themselves would choose for their
own children, they too are split
in their decisions.16–18 Therefore,
when parents of an infant with HLHS
believe that the potential burdens of
interventions outweigh the potential
benefits, they are generally allowed
to opt for EOL care.
In contrast, infants with TA who
do not undergo life-prolonging
interventions have a significantly
different prognosis. Many untreated
infants with TA survive past the
newborn period. Data suggest that
~50% of these infants will die in the
first year of life, and the remaining
children will survive for several
years (and potentially into young
adulthood).33,34 The natural course
of untreated TA is that children’s
pulmonary vascular resistance (PVR)
gradually increases over months to
years. As the PVR increases, children
develop worsening hypoxemia.
Because over time the increased
PVR becomes nonreversible, these
children are not good candidates

for delayed surgical intervention.
Therefore, left untreated the child
with TA will probably experience
a slow decline in health during the
toddler and school-age years, leading
to a long dying process. Because
of the length of the dying process,
palliative interventions are less likely
to be effective, and there is a high risk
that the child will suffer significantly.
Because an infant with TA is likely
to suffer significantly if surgery is
withheld, a decision to forgo lifeprolonging interventions cannot
be considered consistent with that
child’s best interest. Although the
obstetrician was correct in noting
that similar patients should be
treated similarly, the difference
in the natural course of TA and
HLHS leads to different ethically
permissible options for affected
infants. Therefore, the parents
should be educated about the natural
course for their son if life-prolonging
interventions were not provided, and
the providers should explain why
they believe that such a decision is
not appropriate. If the parents persist
in their refusal to give permission
for appropriate intervention, the
team should seek a court order
to authorize medically indicated
treatment.
In general, when we consider a
child’s best interests, we tend to
focus solely on the potential benefits
and burdens of the proposed
intervention. This case illustrates the
importance of considering not only
the potential benefits and burdens of
the proposed treatment but also the
potential benefits and burdens of the
alternatives, including the option to
forgo life-prolonging interventions.
In some cases, such as this, the
alternatives are so clearly contrary
to the patient’s best interests that
a decision to forgo life-prolonging
interventions is not ethically
supportable.

Angira Patel, MD, MPH, Pediatric
Cardiologist, Comments
Congenital heart diseases consisting
of a functional SV (eg, HLHS, TA)
require staged palliation concluding
with a Fontan operation. Over the
last 40 years, surgical technique
has evolved and significant strides
have been made to reduce mortality.
Historically, HLHS has been
technically more challenging with
higher mortality than other types of
SVs, and EOL care has been accepted
an ethically permissible option.
Contemporary results, especially at
high-volume technically excellent
centers, show long-term survival
for HLHS approaching that of other
forms of SV such as TA. Data are
difficult to extrapolate because of
center-related and era effects, but
best estimates range from 80% to
85% for 10-year survival for both
HLHS and TA.7,35 In actuality, all
functional SVs have a similar longterm burden of intensive surgical and
medical therapies. The difference
in mortality between HLHS and
TA is negligible and no longer
sufficient to treat the 2 diagnoses
as different entities for an ethical
analysis. Specifically, life-prolonging
treatment involves ≥2 surgeries
in the first 3 years of life, cardiac
catheterization and interventions,
and lifelong need for monitoring and
treatment of complications including
premature death, ventricular
failure, thromboembolic disease,
arrhythmia, liver disease, proteinlosing enteropathy, and potential
need for heart transplantation. These
interventions are palliative and not
curative. However, the timing of
death without intervention for HLHS
may be different than for TA; infants
with HLHS generally die within 2 to
4 weeks without intervention, but
a small minority of infants with TA
(depending on underlying anatomy)
can survive longer.36
Given surgical and medical advances
leading to similar survival outcomes
for HLHS and TA with the same
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burden of long-term morbidities, the
question now becomes, “Is it ethically
permissible to allow a family to forgo
life-prolonging interventions for a
child with any SV diagnosis? Do we
honor the choice of these parents
that is probably based on their
own family’s individual values and
preferences?” I say yes.
Parents are appropriately tasked
with the role of surrogate decisionmakers for their children because
they are in the best position to
consider the relative weight of
risks and benefits of therapies.
Disagreements within the medical
community occur when there is a
question of whether the parents are
acting in the child’s best interest.
For this child with TA, there are
both early and ongoing morbidities
resulting in what parents perceive to
be suffering and pain for their child.
In defining boundaries of what is
medically and ethically acceptable,
we must weigh the morbidity and
burden of invasive and intensive
therapy against the potential
benefits of those interventions. An
SV palliation by definition involves
lifelong invasive medical care
that may not be the right choice
for some families. These parents,
understanding both known and
unknown risks and benefits and
incorporating their own values and
preferences, have decided that an SV
palliation is not in the best interest of
their child. There is no “right” answer
here. More leeway to parental
decision-making should be allowed
when the burdens of expected
therapy are real and significant,
as they are in this case. Allowing
the family to forgo life-prolonging
therapies is ethically supportable.
However, the parents of this infant
ought to be counseled specifically
on natural history of TA without
intervention (which may be
different from HLHS). If the infant
survives >6 months, a reevaluation
of options would be anticipated,
including consideration of surgical

therapies or continued EOL care. The
subtleties of the diagnosis and the
possibility that death may not come
quickly necessitate a more nuanced
discussion.
I acknowledge the moral distress
of the cardiologist regarding what
is best for the child in the setting
of high probability for survival
(despite the intensive medical and
surgical interventions and potential
morbidities). In this case, the
cardiologist may have to endure this
distress yet stand with the family.
More importantly, the role of the
treating cardiologist continues
to remain crucial: to provide
ongoing support, conveying known
information about how their child
will die without treatment and what
can be done to provide comfort to
optimize their time together.

Steven Leuthner, MD, Neonatologist,
Comments
As the ethics consultant, I would
begin by clarifying 2 issues. The
first is the accuracy of the prenatal
diagnosis. One would not want to
counsel and have the parents make
this prenatal decision unless there is
a reasonable degree of accuracy in
the diagnosis. Although there are a
variety of anatomic situations with
TA, the published accuracy of the
diagnosis is excellent, at 97%.24 Other
independent predictors of poorer
outcome, such as chromosomal or
syndromic findings, might be of value
in the prenatal counseling period as
well.
The second issue to clarify would
be the Internet information the
parents are basing their decision on,
for the single reason of making sure
they are basing their decision on
appropriate data and similar cases.
It would not be surprising if this
Internet information was more about
HLHS than TA. If there was some
misunderstanding or inappropriate
comparisons were being made,
simply reviewing this information
might lead to consensus.

So let us assume the parents’
information is about SV issues and
more likely HLHS, the diagnosis is
correct, and there is no chromosomal
abnormality or other syndrome.
The question then is whether HLHS
and TA are equivalent medically
and therefore ethically. Some might
argue that the presentation of the
infant and the different forms of
TA are applicable. For instance,
approximately one-third of TA cases
have accompanying transposition
of the great arteries that would
necessitate a Norwood palliation
in the newborn period, and twothirds are not transposed and have
a pulmonary outflow track problem
that would necessitate a Blalock–
Taussig shunt or pulmonary band.
The fact remains that no matter
what the initial surgery would be,
the eventual surgical goal is for
an SV Fontan procedure. So what
is the outcome difference for the
Fontan physiology if a patient has
a morphologic right rather than
left ventricle, as well as long-term
outcome of the Fontan procedure?
This gets at the justice issue the
neonatologist is suggesting, that if for
HLHS one would support providing
palliative care, then why not for TA?
Here the data seem mixed. One
study suggests that 10-year survival
is ≤85% of those born with a
dominant left ventricle, as opposed
to only 65% for those born with a
dominant right ventricle.37 A much
larger 40-year follow-up of the
Fontan operation, which includes
a large group of patients with TA,
shows the 10-, 20-, and 30-year
freedom from death or cardiac
transplant being 73%, 59%, and
40%, respectively.35 They describe
the many complications of the
Fontan, including premature death,
ventricular failure, thromboembolic
disease, arrhythmia, liver disease,
and protein-losing enteropathy.
It must be acknowledged that
this is a significant chronic illness
with physical and neurocognitive
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limitations, necessitating procedures
beyond the 3-stage repair if the
child survives the surgeries.
Acknowledging these issues, the
data suggest that at this time it is
reasonable to consider HLHS and TA
as equivalent SV lesions for ethical
decision-making.
If the lesions are equivalent, then
the ethical principle of justice, or
treating equal patients equally, does
come into play. Interestingly, as
the survival of infants with HLHS
undergoing the staged repair has
improved, there continues to be
debate about whether parents
should still be offered palliative
care.19,20 Essentially using the justice
argument, it is often suggested that
with improved HLHS survival and
outcomes there are other cardiac
cases with worse outcomes, yet
palliative care might not be offered
in those. When thinking of justice
in this way, we should beware of
faulty reasoning, because 2 wrongs
would not make a decision right. The
ethical literature continues to show
although the outcomes for HLHS
have improved, and there might
be a recommended medical plan,
they have not yet reached the level
for which palliative care is not an
acceptable choice that parents should
be informed about.21,38,39 In this case,
and at this institution, the standard
practice is to allow parents of infants
with HLHS to choose surgery or EOL
care. The neonatologist is correct
to suggest that based on justice,
because the medical conditions
are reasonably equivalent, if it is
reasonable to offer EOL care in cases
of HLHS, it is reasonable to offer it in
cases of TA.
The underlying ethical question is
whether the survival and quality
of life for these infants meet a
threshold for which the medical team
should consider intervening legally
to override parental authority. In
the case of known complex staged
repair, ethical consistency would
require that a decision to override

parental choice is not only for the
initial neonatal surgery but for all
anticipated procedures. For the
SV path should this also include
transplantation if the Fontan failed?
Overriding parental authority
early also compromises issues
of trust and long-term care for a
medically complicated child. Ethical
frameworks including the best
interest standard, reasonable person
standard, or parental discretion all
support a family having the right to
make a reasonable decision, even
if they are in the minority view.
They maintain that family values
and family impact are reasonable
to consider. These are high-risk
procedures with significant burdens
for the infant and family, not only in
the neonatal period but throughout
life. If we would not mandate things
all the way through, then EOL care at
any stage seems a permissible choice
for a family.
Remembering that this is a prenatal
case, it is important to appreciate
that a prenatal mandate to intervene
after birth could put the family
in a position to consider other
obstetrical options. These could
include termination of pregnancy,
although this can only occur in a few
places nationally at this gestational
age, or even arranging a delivery
plan to avoid the institution. This
would not serve the infant best,
because in the end there must be a
trusting relationship to help develop
a palliative care plan for this infant
who, depending on the outflow track
anatomy, could have different care
needs and projections of neonatal
death.

commentaries illustrate the ways in
which thoughtful people can look at
the same data or the same case and
come up with different responses
about the appropriate course of
action. That does not always happen.
Arguments by bioethicists have
changed the ways in which we
respond to a wide variety of cases.
We used to permit parents to refuse
life-saving surgery for babies with
trisomy 21. We used to refuse to
perform life-saving surgery on babies
with trisomy 18. The borderline
of viability has shifted slowly but
steadily and with it the threshold for
mandating life-sustaining treatment
of premature infants. When
disagreements persist, it suggests a
lack of consensus in the professional
community. In such cases, the proper
thing is to defer to parents. Careful
consideration of the arguments
can help us counsel parents and
ensure that their decisions are
informed decisions. In that sense,
disagreements between bioethicists
are no different, and perhaps no
more common, than disagreements
between cardiologists, policymakers,
or other experts. They signal the
limits of our collective ability to know
what is best and the intensity and
integrity of our efforts to keep finding
out.

ABBREVIATIONS
EOL: end of life
HLHS: hypoplastic left heart
syndrome
PVR: pulmonary vascular
resistance
SV: single ventricle
TA: tricuspid atresia

John D. Lantos, MD, Bioethicist,
Comments
Bioethics is often criticized for not
only having no right answers but for
not even having a method of getting
to a right answer in difficult cases.
Instead, the critics say, there are just
equally powerful arguments on both
sides. That is sometimes true. These
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